<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39110777</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>759</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.</ArticleTitle><Pagination><StartPage>eadi1625</StartPage><MedlinePgn>eadi1625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.adi1625</ELocationID><Abstract><AbstractText>The recent emergence and rapid response to severe acute respiratory syndrome coronavirus 2 was enabled by prototype pathogen and vaccine platform approaches, driven by the preemptive application of RNA vaccine technology to the related Middle East respiratory syndrome coronavirus. Recently, the National Institutes of Allergy and Infectious Diseases identified nine virus families of concern, eight enveloped virus families and one nonenveloped virus family, for which vaccine generation is a priority. Although RNA vaccines have been described for a variety of enveloped viruses, a roadmap for their use against nonenveloped viruses is lacking. Enterovirus D68 was recently designated a prototype pathogen within the family Picornaviridae of nonenveloped viruses because of its rapid evolution and respiratory route of transmission, coupled with a lack of diverse anti-enterovirus vaccine approaches in development. Here, we describe a proof-of-concept approach using a clinical stage RNA vaccine platform that induced robust enterovirus D68-neutralizing antibody responses in mice and nonhuman primates and prevented upper and lower respiratory tract infections and neurological disease in mice. In addition, we used our platform to rapidly characterize the antigenic diversity within the six genotypes of enterovirus D68, providing the necessary data to inform multivalent vaccine compositions that can elicit optimal breadth of neutralizing responses. These results demonstrate that RNA vaccines can be used as tools in our pandemic-preparedness toolbox for nonenveloped viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Nikole L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0002-2307-5529</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0003-8328-3092</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0008-8954-9265</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Garima</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2198-0525</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFadden</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Taishi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1360-5431</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholes</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaelber</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0001-9426-1030</Identifier><AffiliationInfo><Affiliation>Institute for Quantitative Biomedicine, Rutgers, State University of New Jersey, Piscataway, NJ 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawman</LastName><ForeName>David W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-8233-8176</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Rocky Mountain Laboratories, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9448-8227</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Rocky Mountain Laboratories, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khandhar</LastName><ForeName>Amit P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-4049-1855</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berglund</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6551-6636</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-4204-5827</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erasmus</LastName><ForeName>Jesse H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-1612-2697</Identifier><AffiliationInfo><Affiliation>HDT Bio, Seattle, WA 98102, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AI156125</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI169461</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>7</Day><Hour>14</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39110777</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adi1625</ArticleId></ArticleIdList></PubmedData></PubmedArticle>